| Symbol | ATNM |
|---|---|
| Name | ACTINIUM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 PARK AVENUE,23RD FLOOR, NEW YORK, New York, 10017, United States |
| Telephone | (917) 415-1750 |
| Fax | — |
| — | |
| Website | https://www.actiniumpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001388320 |
| Description | Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Additional info from NASDAQ: |
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Read moreActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Read moreActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Read moreActinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Read moreActinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Read moreActinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
Read more(70% Positive) ACTINIUM PHARMACEUTICALS, INC. (ATNM) Announces Clinical Development Update
Read moreActinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Read moreActinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Read moreActinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplan… | Phase2 | Acute Leukemia | Not_Yet_Recruiting | 2026-01-01 | 2034-02-01 | ClinicalTrials.gov |
| NCT07015684 | 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSC… | Phase1 | Sickling Disorder Due to Hemoglobin S | Recruiting | 2025-04-28 | 2032-03-12 | ClinicalTrials.gov |
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | Phase1 | Non Hodgkin Lymphoma | Recruiting | 2025-04-25 | 2030-05-01 | ClinicalTrials.gov |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Phase1 | Acute Myeloid Leukemia | Withdrawn | 2023-03-01 | 2024-09-01 | ClinicalTrials.gov |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | Phase1 | Acute Myeloid Leukemia | Unknown | 2020-01-15 | 2024-06-01 | ClinicalTrials.gov |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Phase1 | Refractory Multiple Myeloma | Terminated | 2016-12-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed … | Phase3 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2016-06-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | Phase1 | AML | Completed | 2012-10-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT00672165 | Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoc… | Phase1 | Leukemia | Completed | 2005-07-01 | 2015-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Planar gamma imaging | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Lintuzumab AC 225 | Other | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT02998047 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| HCT | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Conventional Care | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Iomab-B | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Spironolactone | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Furosemide (Phase 1 only) | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Cytarabine (Phase 1 only) | Other | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Spironolactone | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Lintuzumab-Ac225 | Other | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Planar gamma imaging | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | Other | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Total Body Irradiation (TBI) | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Cyclophosphamide | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Fludarabine | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| 131I-apamistamab | Other | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| CAR-T cell | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Iomab-B | Other | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Total Body Irradiation (TBI) | RADIATION | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Fludarabine | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| 131I-apamistamab | DRUG | Phase PHASE2 | Acute Leukemia | NOT_YET_RECRUITING | NCT07157514 |
| Planar gamma imaging | RADIATION | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Exchange Transfusion | PROCEDURE | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Total Body Irradiation | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Campath | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| Sirolimus | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| 131I-apamistmab | DRUG | Phase PHASE1 | Sickling Disorder Due to Hemoglobin S | RECRUITING | NCT07015684 |
| CAR-T cell | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Azacitidine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Lintuzumab AC 225 | DRUG | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT02998047 |
| HCT | PROCEDURE | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Conventional Care | DRUG | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT02665065 |
| Iomab-B | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | RECRUITING | NCT06768905 |
| Spironolactone | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | UNKNOWN | NCT03867682 |
| Furosemide (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| Lintuzumab-Ac225 | BIOLOGICAL | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT03932318 |
| Cytarabine (Phase 1 only) | DRUG | Phase PHASE1 | AML | COMPLETED | NCT02575963 |
| ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 | BIOLOGICAL | Phase PHASE1 | Leukemia | COMPLETED | NCT00672165 |